Gorilla Technology (Nasdaq: GRRR) announced a $5.6B global pipeline and aims to close $1.3B in long-term contracts by mid-2026, signaling strong momentum across smart city, infrastructure, and public sector projects. Now an official NVIDIA solutions provider and backed by a recent $105M equity raise, Gorilla is accelerating global expansion and solidifying its role as a leading AI infrastructure partner across critical sectors.

FibroBiologics (Nasdaq: FBLG) confirmed its CYWC628 master cell bank can now support manufacturing of CybroCell™, its investigational therapy for degenerative disc disease and cartilage repair—marking a key milestone in platform scalability. This development streamlines production timelines and reinforces the company’s vision of a universal fibroblast-based cell therapy platform for chronic conditions.

Connect Biopharma (Nasdaq: CNTB) announced that its China licensee, Simcere Pharmaceutical, has submitted a New Drug Application for rademikibart—an IL-4Rα-targeting antibody—for atopic dermatitis treatment in adults and adolescents. The filing marks a major regulatory milestone in a market with an estimated 70 million patients, and positions Connect to receive up to $110M in milestone payments plus royalties from future sales.

bioAffinity Technologies (Nasdaq: BIAF) released a compelling case study showcasing how its noninvasive CyPath® Lung test identified Stage 1A lung cancer in a high-risk patient with inconclusive imaging and low modeled malignancy risk. With 92% sensitivity and reimbursed access, CyPath® Lung is emerging as a vital tool for early detection—especially when traditional diagnostics fall short.